The effects of peroral administration of Tofogliflozin(SGLT2 inhibitor) on endogenous glucose production and insulin clearance, single effet and chronic effect.
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2018
At a glance
- Drugs Tofogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Dec 2018 Status changed from not yet recruiting to recruiting.
- 19 Mar 2018 New trial record